Investigating treatments for infants with Neonatal Opioid Withdrawal Syndrome
UAB Clinical Site HEAL Neonatal Opioid Withdrawal Pharmacological Treatments
This study is looking for the best medications to help babies who are going through withdrawal after being exposed to opioids before birth, and it will follow these little ones to see how they develop over time.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10916325 on NIH RePORTER |
What this research studies
This research focuses on infants who experience Neonatal Opioid Withdrawal Syndrome (NOWS) due to prenatal opioid exposure. The study aims to determine the most effective pharmacological treatments for these infants through a multi-center, randomized controlled trial. Conducted at the University of Alabama at Birmingham, the trial will enroll a significant number of affected infants and will utilize established collaborations and resources to ensure comprehensive care and follow-up. The research will also assess neurodevelopmental outcomes in these infants over time.
Who could benefit from this research
Good fit: Ideal candidates for participation are newborns exposed to opioids during pregnancy who are diagnosed with NOWS.
Not a fit: Patients who are not newborns or those who have not been exposed to opioids during pregnancy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols for infants suffering from NOWS, enhancing their recovery and long-term health outcomes.
How similar studies have performed: Previous research has shown promise in assessing pharmacological treatments for NOWS, but this trial aims to provide more definitive comparative effectiveness data.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Ambalavanan, Namasivayam — University of Alabama at Birmingham
- Study coordinator: Ambalavanan, Namasivayam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.